AN2728

AN2728 is a topical anti-inflammatory product candidate for the treatment of psoriasis and atopic dermatitis. AN2728 inhibits PDE4 and reduces the production of TNF-alpha, a precursor of the inflammation associated with psoriasis as well as other cytokines, including IL-12 and IL-23, which are proteins believed to be involved in the inflammation process and immune responses. AN2728 is currently in Phase 2b for psoriasis and Phase 2 for atopic dermatitis.